buyModerate
Manning Paul B bought $7.5M of CADL
director at Candel Therapeutics, Inc.. 1,250,000 shares at an average of $6.00, traded Dec 16, 2024, filed Dec 18, 2024.
Conviction score
50Value
$7.5M
1,250,000 shares
Holdings after
1,303,752
+195% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0000950170-24-137889, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Dec 16, 2024 | POpen-market purchase Common Stockindirect: By Paul B. Manning Revocable Trust | +500,000 | $6.00 | $3.0M | 1,142,406 | Dec 18, 2024 |
| Dec 16, 2024 | POpen-market purchase Common Stockindirect: By BKB Growth Investments, LLC | +750,000 | $6.00 | $4.5M | 1,303,752 | Dec 18, 2024 |
Related signals
Other insiders at Candel Therapeutics, Inc. and this insider’s other filings.
| Score | Side | Company | Insider | Value | Shares | Filed |
|---|---|---|---|---|---|---|
| 45Moderate | sell 4 | CADL Candel Therapeutics, Inc. | Barone Francesca Chief Scientific Officer | $101k | 22,081 | |
| 43Moderate | sell 4 | CADL Candel Therapeutics, Inc. | Nichols William Garrett Chief Medical Officer | $63k | 13,935 | |
| 57Moderate | sell 4 | CADL Candel Therapeutics, Inc. | Tak Paul Peter Chief Executive Officer | $223k | 48,847 | |
| 45Moderate | sell 4 | CADL Candel Therapeutics, Inc. | Tyagarajan Seshu Chief Technology Officer | $93k | 20,392 | |
| 25Weak | sell | CADL Candel Therapeutics, Inc. | Aguilar-Cordova Estuardo owner | $244k | 40,412 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.